Your browser doesn't support javascript.
Duration of Humoral Immunity and Cross-Neutralizing Activity Against the Alpha, Beta, and Delta Variants After Wild-Type Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Prospective Cohort Study.
Noh, Ji Yun; Yang, Jeong Sun; Hwang, Soon Young; Hyun, Hakjun; Seong, Hye; Gu Yoon, Jin; Yoon, Soo Young; Cheong, Hee Jin; Kim, Woo Joo; Park, Woo Jung; Kim, Jun Won; Lee, Joo Yeon; Song, Joon Young.
  • Noh JY; Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea.
  • Yang JS; Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea.
  • Hwang SY; Department of Biostatistics, Korea University College of Medicine, Seoul, Republic of Korea.
  • Hyun H; Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea.
  • Seong H; Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea.
  • Gu Yoon J; Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea.
  • Yoon SY; Department of Laboratory Medicine, Korea University College of Medicine, Seoul, Republic of Korea.
  • Cheong HJ; Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea.
  • Kim WJ; Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea.
  • Park WJ; Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea.
  • Kim JW; Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea.
  • Lee JY; Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea.
  • Song JY; Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea.
J Infect Dis ; 226(6): 975-978, 2022 09 21.
Article in English | MEDLINE | ID: covidwho-1752117
ABSTRACT
A prospective cohort study was conducted for adults with a diagnosis of with coronavirus disease 2019 (COVID-19). Convalescent blood samples were obtained 4, 6, and 11 months after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The seropositivity of anti-spike antibody was maintained in all patients (100%) until 11 months after COVID-19 diagnosis. Neutralizing antibody levels against wild-type SARS-CoV-2 gradually decreased but remained positive in >50% of patients 11 months after diagnosis in 98.5% (67 of 68) at 4 months, 86.8% (46 of 53) at 6 months, and 58.8% (40 of 68) at 11 months. However, cross-neutralizing activity against the Beta and Delta variants was attenuated 2.53-fold and 2.93-fold, respectively, compared with the wild-type strain.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study / Randomized controlled trials Topics: Variants Limits: Adult / Humans Language: English Journal: J Infect Dis Year: 2022 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Diagnostic study / Observational study / Prognostic study / Randomized controlled trials Topics: Variants Limits: Adult / Humans Language: English Journal: J Infect Dis Year: 2022 Document Type: Article